Aim: To rationally evaluate the effect of S-1 vs capecitabine for the treatment of gastric cancer.
Methods: MEDLINE, EMBASE, Cochrane Controlled Trials Register, Google Scholar, and China Journal Full Text Database were accessed to collect clinical randomized controlled trials regarding the effect of S-1 vs capecitabine for the treatment of gastric cancer patients. Statistical analysis was performed by meta-analysis. Four randomized controlled trials met the inclusion criteria.
Results: Compared with capecitabine regimens, the 1-year survival rate in gastric cancer patients was 0.80 (95%CI: 0.52-1.21, P = 0.29). The overall response rate of S-1 vs capecitabine was 0.94 (95%CI: 0.59-1.51, P = 0.93). Compared with capecitabine regimens, the most frequent hematologic toxicities were neutropenia (OR = 0.99, 95%CI: 0.65-1.49, P = 0.94) and thrombocytopenia (OR = 0.72, 95%CI: 0.31-1.67, P = 0.44). The most frequent non-hematologic toxicities included nausea (OR = 0.85, 95%CI: 0.56-1.28, P = 0.43) and hand-foot syndrome (OR = 0.16, 95%CI: 0.10-0.27, P < 0.00001).
Conclusion: The existing studies suggest that S-1 is not more effective than capecitabine in the treatment of gastric cancer patients, but does exhibit less toxicity with regard to hand-foot syndrome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394098 | PMC |
| http://dx.doi.org/10.3748/wjg.v21.i14.4358 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The application of immunotherapy combined with taxanes in second‑line treatment of advanced HER2 negative gastric cancer.
Mol Clin Oncol
January 2025
Department of Oncology, Shanghai Changhai Hospital, Naval Medical University, Shanghai 200433, P.R. China.
Human epidermal growth factor receptor-2 (HER2) negative advanced gastric cancer (GC) has a high global incidence and mortality rate with limited options for second-line treatment. Monotherapy is not effective and the combination of chemotherapy and immunotherapy has not yet been included in the guidelines. The present study aimed to explore a new treatment approach by conducting a single-center, retrospective, observational real-world study.
View Article and Find Full Text PDFIschemic cardiopathy induced by capecitabine in gastric cancer: The role of dihydropyrimidine dehydrogenase metabolites.
Therapie
October 2024
Department of Medical and Clinical Pharmacology, Faculty of Medicine, Centre of PharmacoVigilance and Pharmacoepidemiology, Toulouse University Hospital, 31000 Toulouse, France. Electronic address:
Objectives: Fluoropyrimidine-based therapies, 5-fluorouracil (5-FU) and its oral prodrugs, capecitabine and tegafur/oteracil/gimeracil (S-1), are pivotal drugs to treat gastric cancer. Fluoropyrimidines are associated with cardiotoxicity including ischemic cardiopathy. The mechanisms of ischemic cardiopathy are considered to be multifactorial, potentially involving metabolites of 5-FU generated by the dihydropyrimidine dehydrogenase (DPD).
View Article and Find Full Text PDFEfficacy of chemotherapy for patients with gastric cancer with early recurrence during or after adjuvant chemotherapy with S-1 alone: a multicenter retrospective study.
Sci Rep
September 2024
Department of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Article Synopsis
- * Most patients received paclitaxel-based treatments (49%), followed by fluoropyrimidines plus platinum (44%), and irinotecan (7%), with overall response rates of 28.7% and disease control rates of 54.1%.
- * Results indicated a median progression-free survival (PFS) of 5.1 months and overall survival (OS) of 12.9 months, with the combination of paclitaxel and ramucirumab
Maintenance treatment with oral anticancer agents after first-line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.
Eur Arch Otorhinolaryngol
August 2024
Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Youyi Road, Yuzhong District, Chongqing, 400016, China.
Objective: Maintenance therapy following first-line chemotherapy is of particular significance in patients diagnosed with recurrent or metastatic nasopharyngeal carcinoma (NPC). We conducted a meta-analysis to investigate the impact of maintenance therapy (MT) on the survival prognosis of individuals with recurrent or metastatic NPC.
Methods: The databases Embase, PubMed, and the Cochrane Library were thoroughly searched in a comprehensive manner.
A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group.
Jpn J Clin Oncol
October 2024
Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.
Article Synopsis
- The study analyzed the use and costs of first-line chemotherapy for advanced/recurrent gastric cancer (AGC) in Japan, focusing on patients with HER2-negative AGC treated in 2022.
- A total of 2113 patients were evaluated, revealing that expensive chemotherapy regimens (costing over 500,000 JPY per month) primarily included triplet therapy with fluoropyrimidine, oxaliplatin, and the immune inhibitor nivolumab.
- The findings showed that these costly regimens were utilized by 67% of patients, including a significant portion of older patients, highlighting the need for more research on the economic implications of such drugs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!